Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration

DOI Web Site Web Site 被引用文献15件

抄録

<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>Etanercept and infliximab are tumor necrosis factor (TNF) antagonists that have been recently approved for the treatment of rheumatoid arthritis (RA) and Crohn's disease (CD). This study was undertaken to investigate the occurrence of lymphoproliferative disorders in patients treated with these agents.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Relevant data in the MedWatch postmarket adverse event surveillance system run by the US Food and Drug Administration were reviewed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We identified 26 cases of lymphoproliferative disorders following treatment with etanercept (18 cases) or infliximab (8 cases). The majority of cases (81%) were non‐Hodgkin's lymphomas. The interval between initiation of therapy with etanercept or infliximab and the development of lymphoma was very short (median 8 weeks). In 2 instances (1 infliximab, 1 etanercept), lymphoma regression was observed following discontinuation of anti‐TNF treatment, in the absence of specific cytotoxic therapy directed toward the lymphoma.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Although data from a case series such as this cannot establish a clear causal relationship between exposure to these medications and the risk of lymphoproliferative disease, the known predisposition of patients with RA and CD to lymphoma, the known excess of lymphoma in other immunosuppressed populations, and the known immunosuppressive effects of the anti‐TNF drugs provide a biologic basis for concern and justification for the initiation of additional epidemiologic studies to formally evaluate this possible association.</jats:p></jats:sec>

収録刊行物

被引用文献 (15)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ